Aegerion 2% convertibles to be convertible into QLT shares post-merger

By Wendy Van Sickle

Columbus, Ohio, June 16 – Aegerion Pharmaceuticals, Inc.’s 2% convertible senior notes due 2019 will become convertible into common shares of QLT Inc. as part of a merger agreement under which QLT is set to acquire Aegerion, according to an 8-K filing with the Securities and Exchange Commission.

Following consummation of the acquisition, QLT, which will be renamed Novelion Therapeutics Inc., will enter into a supplemental indenture to the convertibles’ governing indenture giving effect to the change, according to the filing.

Aegerion is a specialty pharmaceutical company based in Cambridge, Mass. QLT is a Vancouver, B.C.-based biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.